Nektar Therapeutics
NKTR
163 hedge funds and large institutions have $1.86B invested in Nektar Therapeutics in 2014 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 49 increasing their positions, 50 reducing their positions, and 19 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
111% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 19
39% more call options, than puts
Call options by funds: $4.03M | Put options by funds: $2.89M
30% more capital invested
Capital invested by funds: $1.43B → $1.86B (+$432M)
12% more funds holding
Funds holding: 145 → 163 (+18)
2% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$32.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.8M |
| 3 |
PC
PointState Capital
New York
|
+$14.2M |
| 4 |
DFO
Duquesne Family Office
New York
|
+$9.33M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$7.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$22M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$16M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$15.7M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$12.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$5.31M |
NKTR Hedge Fund Activity: Q4 2014 in Review
163 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2014, worth a combined $1.86B — up 30% from $1.43B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new NKTR positions and 19 closed out — a net gain of 21 holders — while 49 added to existing stakes and 50 trimmed.
The largest buyer was Invesco, adding an estimated $32.7M. The largest seller was NEA Management Company, exiting entirely with an estimated $22M sold.
- 163 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2014, up from 145 in Q3 2014.
- Funds reported $1.86B of Nektar Therapeutics stock for Q4 2014, up 30% quarter-over-quarter.
- 40 funds opened new Nektar Therapeutics positions in Q4 2014 and 19 closed out, a net change of +21 holders.
- The largest Nektar Therapeutics buyer in Q4 2014 was Invesco, an estimated $32.7M added.
- The largest Nektar Therapeutics seller in Q4 2014 was NEA Management Company, an estimated $22M sold.
Based on aggregated 13F filings for Q4 2014.